RBC Bioscience

RBC Bioscience Capital Expenditures

The Capital Expenditures (CapEx) of RBC Bioscience (6848.TWO) as of Oct 22, 2026 is -10.32 M TWD. In the previous year, Capital Expenditures (CapEx) was -6.46 M TWD — a change of 59.68% (lower).

Capital Expenditures

-10.32 MTWD

YoY

59.68%

Last updated:

Capital Expenditures (CapEx) of RBC Bioscience is 2024 -10.32 M TWD. Capital Expenditures (CapEx) of RBC Bioscience was 2023 -6.46 M TWD. It decreases by 59.68% lower compared to the previous year.

The RBC Bioscience Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-70.03 M TWD
Jan 1, 2019
-9.08 M TWD
Jan 1, 2020
-118.41 M TWD
Jan 1, 2021
-450.12 M TWD
Jan 1, 2022
-10.05 M TWD
Jan 1, 2023
-6.46 M TWD
Jan 1, 2024
-10.32 M TWD
The RBC Bioscience Capital Expenditures history
YEARCapital ExpendituresYoY
-10.32 MTWD+59.68%
-6.46 MTWD-35.66%
-10.05 MTWD-97.77%
-450.12 MTWD+280.13%
-118.41 MTWD+1,203.50%
-9.08 MTWD-87.03%
-70.03 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Capital Expenditures (CapEx) of RBC Bioscience is -10.32 M TWD in 2024.

Capital Expenditures (CapEx) of RBC Bioscience changed from -6.46 M TWD to -10.32 M TWD, representing a 59.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s RBC Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RBC Bioscience

All Key Metrics — RBC Bioscience